(Q35164752)

6 August 2017

1 reference

title

Pharmacological methods to overcome IFN-beta antibody formation in the treatment of multiple sclerosis (English)

1 reference

6 August 2017

Francesca Bagnato

1

1 reference

6 August 2017

Carlo Pozzilli

series ordinal

2

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

Expert Opinion on Investigational Drugs

6 August 2017

published in

1 reference

6 August 2017

volume

12

1 reference

6 August 2017

issue

7

1 reference

6 August 2017

page(s)

1153-1163

1 reference

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1153

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1153

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1153

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1153

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1153

Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1153

Neutralising and binding anti-interferon-beta-I b (IFN-beta-I b) antibodies during IFN-beta-I b treatment of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1153

Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1153

Correlation of the appearance of anti-interferon antibodies during treatment and dimunition of efficacy: summary of an International Workshop on Anti-Interferon Antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1153

Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1153

Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1153

The small subunit of HL-A antigens is beta 2-microglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1153

The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1153

Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1153

Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1153

Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1153

A one-year study on the pharmacodynamic profile of interferon-beta1a in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1153

Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1153

The pathology of multiple sclerosis and its evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1153

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1153

Immunoglobulin-containing cells in multiple-sclerosis plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1153

Effect of steroids on Gd-enhancing lesions before and during recombinant beta interferon 1a treatment in relapsing remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1153

Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1153

Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1153

Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1153

Plasmapheresis combined with interferon: an effective therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1153

Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1153

Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1153

Maintenance of serological memory by polyclonal activation of human memory B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1153

The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1153

Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1153

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1153

10.1517/13543784.12.7.1153

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference